Novo CEO tells CNBC why drugmaker is rebranding, needs to ‘rethink’ obesity strategy
Novo Nordisk is entering a new era under the shortened brand name Novo, signaling a sweeping effort to modernize its corporate identity and reclaim ground in the fiercely contested obesity drug market. Speaking with CNBC, CEO Mike Doustdar explained that the rebranding is part of a larger package designed to evolve the company’s internal culture
